Individualised immunosuppression with intravenously administered donor-derived modified immune cells compared with standard of care in living donor kidney transplantation (TOL-2 Study): protocol for a multicentre, open-label, phase II, randomised controlled trial

INTRODUCTION: Donor-derived modified immune cells (MIC) induced long-term specific immunosuppression against the allogeneic donor in preclinical models of transplantation. In a phase I clinical trial (TOL-1 Study), MIC treatment resulted in a cellular phenotype that was directly and indirectly suppr...

Descripción completa

Detalles Bibliográficos
Autores principales: Morath, Christian, Schmitt, Anita, Schmitt, Michael, Wang, Lei, Kleist, Christian, Opelz, Gerhard, Süsal, Caner, Tran, T. Hien, Scherer, Sabine, Schwenger, Vedat, Kemmner, Stephan, Fischereder, Michael, Stangl, Manfred, Hauser, Ingeborg A., Sommerer, Claudia, Nusshag, Christian, Kälble, Florian, Speer, Claudius, Benning, Louise, Bischofs, Christian, Sauer, Sandra, Schubert, Maria-Luisa, Kunz, Alexander, Hückelhoven-Krauss, Angela, Neuber, Brigitte, Mehrabi, Arianeb, Schwab, Constantin, Waldherr, Rüdiger, Sander, Anja, Büsch, Christopher, Czock, David, Böhmig, Georg A, Reiser, Jochen, Roers, Axel, Müller-Tidow, Carsten, Terness, Peter, Zeier, Martin, Daniel, Volker, Schaier, Matthias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Renal Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9660568/
https://www.ncbi.nlm.nih.gov/pubmed/36368749
http://dx.doi.org/10.1136/bmjopen-2022-066128

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9660568/
https://www.ncbi.nlm.nih.gov/pubmed/36368749
http://dx.doi.org/10.1136/bmjopen-2022-066128

Ejemplares similares